GlassScriptPhysician profile
Brian Steven Taylor
NPI 1992905723
$2,984.90
in general payments reported to CMS, 2019-2025
18 companies · $761 in 2025
The $761 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $107 · 2021: $267 · 2022: $834 · 2023: $333 · 2024: $330 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $794.91 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $525.62 | 2019-2025 | Spravato |
| Alkermes, INC. | $362.44 | 2019-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $239.12 | 2019-2025 | Rexulti |
| Abbvie INC. | $183.52 | 2021-2025 | |
| Lundbeck LLC | $172.59 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $129.48 | 2025 | Cobenfy |
| Tris Pharma INC | $125.00 | 2022 | |
| Biogen, INC. | $118.08 | 2025 | Zurzuvae |
| Neurocrine Biosciences, INC. | $104.08 | 2019-2024 | Ingrezza |
| Bausch Health US, LLC | $69.59 | 2019-2025 | Aplenzin, Wellbutrin |
| Sage Therapeutics, LLC | $33.33 | 2024 | |
| Allergan, INC. | $29.99 | 2020 | |
| Tempus Ai, INC | $25.18 | 2024 | |
| Ironshore Pharmaceuticals INC. | $23.89 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $18.95 | 2024 | Quviviq |
| Neos Therapeutics, LP | $16.89 | 2025 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.